 Agios is planning to file its sickle cell disease (SCD) candidate mitapivat with the FDA under the accelerated pathway, based on feedback from the US regulator at a recent meeting. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
